In September, Indian drug manufacturer Alembic received a tentative nod from the US Food and Drug Administration (FDA) to manufacture generic alogliptin as well as the alogliptin/metformin fixed-drug ...
SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...
Researchers found that the rate difference of depression was 3.48 per 1000 person-years between GLP-1 RA users and SGLT-2i users. HealthDay News — For older adults with type 2 diabetes (T2D), use of ...
The study published in eClinicalMedicine by Huilin Tang and colleagues from the University of Pennsylvania Perelman School of ...
Among the emerging therapeutic strategies for type 2 diabetes (T2D), G protein-coupled receptor 119 (GPR119) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated promise due to ...
A collaboration between a drug plan and clinical pharmacists led to nearly 50% of members successfully switching to a preferred dipeptidyl-peptidase-4 inhibitor. Results: Initially, more than 50% of ...
Among the emerging therapeutic strategies for type 2 diabetes (T2D), G protein-coupled receptor 119 (GPR119) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have demonstrated promise due to ...
A recent study published in the International Journal of Molecular Sciences revealed that patients initiating sodium–glucose ...
SGLT2 inhibitors were associated with a lower or similar fracture risk compared with incretin-based antidiabetic agents in postmenopausal women with type 2 diabetes, according to a claims-based study ...
Modestly lower risk for depression seen compared with DPP-4i use, but not compared with SGLT-2i use. (HealthDay News) — For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results